Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RKD002
- Development stage
- Preclinical
- Lead developer
- RevolKa
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
RKD002 is a preclinical-stage mRNA-based therapeutic being developed by RevolKa for the treatment of an undisclosed rare disease. The drug utilizes RevolKa's proprietary protein engineering platform, which combines directed evolution with artificial intelligence (AI) to design optimized proteins. RKD002 specifically consists of a gain-of-function (GOF)-enhanced mRNA designed to express a novel, AI-optimized enzyme. This approach aims to address rare genetic disorders by providing functional enzymatic activity that is superior to the wild-type protein. As of 2024, the specific molecular target and the exact rare disease indication remain undisclosed by the sponsor.
Beyond the preview
Go deeper on RKD002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RKD002.